Mylan's Nebivolol NDA User Fee Date Extended To May 31
This article was originally published in The Pink Sheet Daily
Executive Summary
Three-month delay means the beta blocker's user fee deadline will no longer coincide with the Feb. 28 "walk-away" date for Mylan's acquisition of King. Extension stems from recent submission "of an additional presentation of already submitted data from the nebivolol NDA," Mylan says.
You may also be interested in...
Mylan Seeks Licensing Partner, Heart Failure Indication For Nebivolol
The company hopes to announce a partner for nebivolol this fall, roughly the same timeframe targeted for discussions with FDA on data needed for a congestive heart failure claim. The beta blocker is “approvable” at FDA for hypertension; Mylan expects to respond to the agency by year-end.
Mylan Seeks Licensing Partner, Heart Failure Indication For Nebivolol
The company hopes to announce a partner for nebivolol this fall, roughly the same timeframe targeted for discussions with FDA on data needed for a congestive heart failure claim. The beta blocker is “approvable” at FDA for hypertension; Mylan expects to respond to the agency by year-end.
Mylan's Nebivolol Is "Approvable" At FDA
The beta blocker's user fee date had been extended by three months following submission of additional analysis. Mylan expects the anti-hypertensive to be the cornerstone of its brand division.